Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB8 | P28062 | 2/20 | 0.41 |
| ▸ | CBFB | Q13951 | 1/20 | 0.33 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.32 |
| ▸ | DHODH | Q02127 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3469733 | 0.85 | CBFB (0.44) | PSMB8CBFBEGLN1DHODH | |
| SCHEMBL31748505 | 0.71 | CBFB (0.33) | CBFBEGLN1 | |
| SCHEMBL5904354 | 0.70 | PSMB8 (0.54) | PSMB8CBFBEGLN1 | |
| SCHEMBL31748504 | 0.70 | EGLN1 (0.44) | EGLN1DHODH | |
| SCHEMBL23449132 | 0.69 | PSMB8 (0.41) | PSMB8 | |
| SCHEMBL31748582 | 0.69 | EGLN1 (0.38) | CBFBEGLN1DHODH | |
| SCHEMBL9391888 | 0.69 | RIPK1 (0.53) | PSMB8CBFBEGLN1 | |
| SCHEMBL6583421 | 0.66 | PSMB8 (0.39) | PSMB8EGLN1 | |
| SCHEMBL20479488 | 0.65 | PSMB8 (0.65) | PSMB8 | |
| SCHEMBL23448501 | 0.64 | NQO2 (0.43) | PSMB8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388571-A1 | AMP-ACTIVATED PROTEIN KINASE MODULATOR COMPOUNDS AND USES THEREOF | BIOLEXIS THERAPEUTICS INC (US) | 2025-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388571-A1 | AMP-ACTIVATED PROTEIN KINASE MODULATOR COMPOUNDS AND USES THEREOF | PRKAB2, PRKAB1, PRKAR2B | PSMB8 2401/4885CBFB 1110/4885EGLN1 3554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.